T 0670/20 (Pharmaceutcial composition/SANKYO) vom 02.12.2022
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2022:T067020.20221202
- Datum der Entscheidung
- 2. Dezember 2022
- Aktenzeichen
- T 0670/20
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 08720658.7
- Verfahrenssprache
- Englisch
- Verteilung
- An die Kammervorsitzenden verteilt (C)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- Zusammenfassung von EPC2000 Art 054
- Bezeichnung der Anmeldung
- PHARMACEUTICAL COMPOSITION
- Name des Antragstellers
- Daiichi Sankyo Company, Limited
- Name des Einsprechenden
- Hexal AG
Generics [UK] Ltd - Kammer
- 3.3.07
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 013(1)
- Schlagwörter
- Amendments - allowable (yes)
Novelty - public prior use (no)
Inventive step - bonus effect (no)
Amendment to appeal case - justification by party (yes) - Orientierungssatz
- The clinical trials were carried out in accordance with the EMEA Guidelines for Good Clinical Practice. These guidelines explicitly require adherence to the prescribed protocol and assurance of drug accountability. This set-up of the trials implies that the patients who decided to participate in the trials agreed, following their informed consent, to use the provided medication according to instruction or to return the unused medication. Accordingly, the participating patients who were provided with the tablets under investigation entered into a special relationship with the investigators of the trials and were with regard to the provided tablets not members of the public that could freely dispose over these tablets. (see section 4.3)
- Zitierende Akten
- -
Order
For these reasons it is decided that:
The appeals are dismissed.